PMID- 22183078
OWN - NLM
STAT- MEDLINE
DCOM- 20120628
LR  - 20151119
IS  - 1536-0210 (Electronic)
IS  - 0020-9996 (Linking)
VI  - 47
IP  - 3
DP  - 2012 Mar
TI  - Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: 
      intraindividual comparison with gadopentetate dimeglumine.
PG  - 183-8
LID - 10.1097/RLI.0b013e318236e354 [doi]
AB  - OBJECTIVES: To compare 0.15 mmol/kg gadobutrol with 0.20 mmol/kg gadopentetate 
      dimeglumine with regard to late gadolinium enhancement (LGE) of infarcted 
      myocardium at magnetic resonance (MR) imaging. MATERIALS AND METHODS: Twenty 
      patients with history of chronic myocardial infarction underwent 2 cardiac MR 
      examinations at 1.5 Tesla. For the evaluation of myocardial infarction, late 
      gadolinium enhancement (LGE) imaging was performed with an inversion 
      recovery-prepared gradient-echo sequence 15 minutes after administration of 
      either gadobutrol (r1 = 5.2 mmol(-1)s(-1)) or gadopentetate dimeglumine (r1 = 4.1 
      mmol(-1)s(-1)). The dose of the contrast agents was adjusted based on the 
      relaxivity of both contrast agents. Hence, gadobutrol and gadopentetate 
      dimeglumine were administered at 0.15 mmol/kg and 0.20 mmol/kg, respectively. 
      Contrast-to-noise ratios (CNR) between infarcted myocardium and remote myocardium 
      (CNR remote) and between infarcted myocardium and left ventricular lumen (CNR 
      lumen) were assessed by 2 independent readers. Additionally, infarct size was 
      assessed semiautomatically by using a threshold of 5 standard deviations above 
      the mean signal intensity of remote myocardium. RESULTS: Subendocardial or 
      transmural LGE was present in 16 of 20 (80%) patients. The optimal inversion time 
      for LGE imaging did not differ significantly between gadobutrol and gadopentetate 
      dimeglumine (275 +/- 21 milliseconds [range, 240-320 milliseconds] and 282 +/- 23 
      milliseconds [range, 240-330 milliseconds], respectively; P = 0.32). The CNR 
      remote after administration of gadobutrol (40.0 +/- 4.6; 95% confidence interval 
      [CI]: 30.3; 49.7) and gadopentetate dimeglumine (40.6 +/- 4.6; 95% CI: 30.9; 50.3) 
      did not show significant differences (P = 0.90), whereas gadobutrol yielded a 
      significantly higher CNR lumen (6.2 +/- 3.6; 95% CI: -1.5; 13.9) compared with 
      gadopentetate dimeglumine (0.8 +/- 3.6; 95% CI: -6.9; 8.5). Infarct size after 
      administration of gadobutrol (23.7 +/- 4.7 mL; 95% CI: 13.6; 33.7) and 
      gadopentetate dimeglumine (23.7 +/- 4.7 mL;95% CI: 13.7; 33.8) was not 
      statistically different (P = 0.94). There was an excellent correlation between 
      gadobutrol- and gadopentetate dimeglumine-enhanced assessment of infarct size 
      (Spearman r = 0.99 and r = 0.97 for reader 1 and 2, respectively). CONCLUSION: 
      This pilot study shows that 0.15 mmol/kg gadobutrol is an effective contrast 
      agent for LGE imaging with better delineation of infarcted myocardium from left 
      ventricular lumen than 0.20 mmol/kg gadopentetate dimeglumine.
FAU - Durmus, Tahir
AU  - Durmus T
AD  - Department of Radiology, Charite-Universitatsmedizin Berlin, Charite Campus 
      Mitte, Berlin, Germany.
FAU - Schilling, Rene
AU  - Schilling R
FAU - Doeblin, Patrick
AU  - Doeblin P
FAU - Huppertz, Alexander
AU  - Huppertz A
FAU - Hamm, Bernd
AU  - Hamm B
FAU - Taupitz, Matthias
AU  - Taupitz M
FAU - Wagner, Moritz
AU  - Wagner M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Invest Radiol
JT  - Investigative radiology
JID - 0045377
RN  - 0 (Contrast Media)
RN  - 0 (Organometallic Compounds)
RN  - 1BJ477IO2L (gadobutrol)
RN  - K2I13DR72L (Gadolinium DTPA)
SB  - IM
MH  - Chronic Disease
MH  - Confidence Intervals
MH  - *Contrast Media
MH  - Female
MH  - *Gadolinium DTPA
MH  - Humans
MH  - Magnetic Resonance Imaging/*instrumentation/methods
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*diagnosis/pathology
MH  - *Organometallic Compounds
MH  - Pilot Projects
MH  - Statistics, Nonparametric
EDAT- 2011/12/21 06:00
MHDA- 2012/06/29 06:00
CRDT- 2011/12/21 06:00
PHST- 2011/12/21 06:00 [entrez]
PHST- 2011/12/21 06:00 [pubmed]
PHST- 2012/06/29 06:00 [medline]
AID - 10.1097/RLI.0b013e318236e354 [doi]
PST - ppublish
SO  - Invest Radiol. 2012 Mar;47(3):183-8. doi: 10.1097/RLI.0b013e318236e354.